Back to results
US 2011/0217267 A1Published application
Gene therapy vectors and cytosine deaminases
AssigneeTocagen Inc.
InventorsHarry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
Life of this patent
Estimating the term…
Abstract
This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
Claims58
An isolated polynucleotide comprising:
- a human codon optimized polynucleotide encoding a polypeptide of SEQ ID NO:4, wherein the polypeptide comprises cytosine deaminase (CD) activity.
An isolated polynucleotide comprising:
- a first coding sequence encoding a polypeptide having cytosine deaminase activity;
- and
- a second coding sequence encoding a polypeptide having URPT or OPRT activity,
- wherein the first coding sequence is operably linked to the second coding sequence.
1 more element
An isolated polynucleotide comprising from 5′ to 3′:
- a CMV-R-U5 fusion of the immediate early promoter from human cytomegalovirus to an MLV R-U5 region;
- a PBS, primer binding site for reverse transcriptase;
- a 5′ splice site;
- ψ packaging signal;
- a gag coding sequence for MLV group specific antigen;
- a pol coding sequence for MLV polymerase polyprotein;
- a 3′ splice site;
- a 4070A env coding sequence for envelope protein of MLV strain 4070A;
- an internal ribosome entry site (IRES) from encephalomyocarditis virus;
- a modified cytosine deaminase coding sequence;
- a polypurine tract;
- and
- a U3-R-U5 MLV long terminal repeat.
10 more elements
Dependencies are inferred from the claim text.